YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
CAD $79 million term loan replaces USD $56 million term loan CAD $107 million (~USD $77.5 million) total facility provides enhanced financial flexibility CAD-denominated facility reduces FX exposure and lowers interest rate TORONTO, Aug. 2…
John Hanna appointed Interim CFO to replace departing CFO Tim Hendrickson TORONTO, Dec. 18, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment…
It's not possible to invest over long periods without making some bad investments. But you want to avoid the really big losses like the plague. So spare a thought for the long term shareholders of HLS Therapeutics Inc. (TSE:HLS); the share…
The latest analyst coverage could presage a bad day for HLS Therapeutics Inc. (TSE:HLS), with the analysts making across-the-board cuts to their statutory estimates that might leave shareholders a little shell-shocked. Revenue and earnings…
Analysis Also Found Icosapent Ethyl Was Associated with a 41% Reduction in Total Events Compared with Placebo Subgroup Almost Exclusively Comprised of Patients with Established Cardiovascular Disease Findings Continue to Reinforce the Scie…
TORONTO, Nov. 9, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces its financi…
TORONTO, Oct. 26, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q3 Fiscal 2023 financial results on Thursday, November 9, 2023. The Company will hold a conference call that same…
TORONTO, Sept. 6, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system ("CNS") and cardiovascular markets, announces that Craig Millian, Chief Executive Officer…
We feel now is a pretty good time to analyse HLS Therapeutics Inc.'s (TSE:HLS) business as it appears the company may be on the cusp of a considerable accomplishment. HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and…
Term is extended, borrowing capacity increases, financial flexibility improves, and interest rates remain relatively unchanged. TORONTO, Aug. 14, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical comp…
TORONTO, Aug. 10, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system ("CNS") and cardiovascular markets, announces its financial results for the three- and si…
TORONTO, Aug. 3, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q2 Fiscal 2023 financial results on Thursday, August 10, 2023. The Company will hold a conference call that same da…
John Welborn, Jr. is appointed Chair of the Board, succeeding Greg Gubitz, who is retiring John Hanna is appointed to the HLS Board as an independent director TORONTO, June 22, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (T…
TORONTO, June 16, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces voting results from its Annual Meeting of Shareholde…
HLS Directors J. Spencer Lanthier and Don DeGolyer will not be standing for re-election at the 2023 AGM Director Greg Gubitz to retire following 2023 AGM and Polar nominee to be appointed to the Board TORONTO, June 8, 2023 /CNW/ - HLS Ther…
TORONTO, May 11, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system ("CNS") and cardiovascular markets, announces its financial results for the three-month pe…
TORONTO, May 3, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q1 Fiscal 2023 financial results on Thursday, May 11, 2023. The Company will hold a conference call that same day at…
TORONTO, April 21, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system ("CNS") and cardiovascular markets, announces that Tim Hendrickson, Chief Financial Offi…
• Craig Millian to replace retiring CEO, Gilbert Godin, on May 1, 2023 TORONTO, April 17, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system ("CNS") and cardi…
TORONTO, March 16, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system ("CNS") and cardiovascular markets, announces its financial results for the three- and t…
TORONTO, March 2, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q4 and Fiscal 2022 financial results on Thursday, March 16, 2023. The Company will hold a conference call that sam…
TORONTO, Nov. 29, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that Dr. Kyle Dempsey has been appointed to the boa…
TORONTO, Nov. 14, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, CEO, and Tim Hendrickson, CFO, w…
Q3 2022 revenue of $15.7 million, Adjusted EBITDA of $6.0 million and cash from operations of $4.2 million. Total Vascepa prescriptions grew 14% sequentially and 89% year-over-year. 2,800 physicians have prescribed Vascepa, up 16% sequenti…
Independent RESPECT-EPA Study Now Third in a Series of Trials to Underscore Cardiovascular Risk Reduction Benefits of Eicosapentaenoic Acid ("EPA") for Patients TORONTO, Nov. 7, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (…
TORONTO, Oct. 27, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q3 Fiscal 2022 financial results on Thursday, November 10, 2022. The Company will hold a conference call that same…
TORONTO, Oct. 3, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system and cardiovascular markets, announces updates to its credit agreement and senior secured t…
The board of HLS Therapeutics Inc. (TSE:HLS) has announced that it will pay a dividend of $0.05 per share on the 15th of December. This means the dividend yield will be fairly typical at 2.3%. While the dividend yield is important for inco…
TORONTO, Sept. 15, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces that it will be participating in Renmark Financial…
The board of HLS Therapeutics Inc. (TSE:HLS) has announced that it will pay a dividend of $0.05 per share on the 15th of December. Including this payment, the dividend yield on the stock will be 1.5%, which is a modest boost for shareholde…
Q2 2022 revenue of $15.5 million, Adjusted EBITDA of $6.2 million and cash from operations of $3.5 million. Total Vascepa prescriptions grew 88% year-over-year, reflecting sequential growth of total and new Vascepa® prescriptions in Q2 202…
Reimbursement coverage for Vascepa in Canada is now approximately 70% for publicly covered lives and private coverage is now in excess of 95% for those that are in-label Public reimbursement for Vascepa is now available in Ontario, Quebec,…
TORONTO, July 28, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q2 Fiscal 2022 financial results on Thursday, August 11, 2022. The Company will hold a conference call that same d…
HLS Therapeutics Inc. (TSE:HLS) will pay a dividend of $0.05 on the 15th of September. This payment means the dividend yield will be 1.5%, which is below the average for the industry. Check out our latest analysis for HLS Therapeutics HLS…
Reimbursement for Vascepa in Canada is now at more than 65% for publicly covered lives and private coverage is in excess of 95% for those who are in-label Public reimbursement for Vascepa is now available in Ontario, Quebec, New Brunswick,…
For many investors, the main point of stock picking is to generate higher returns than the overall market. But the risk of stock picking is that you will likely buy under-performing companies. We regret to report that long term HLS Therape…